MARLBOROUGH, Mass.,
May 13, 2016 /PRNewswire/ -- Boston
Scientific (NYSE: BSX) today announced the schedule of key data
that will be featured at the annual EuroPCR Scientific Program,
May 17-20 in Paris.
Data from the 1,000-patient EWOLUTION registry, the
observational, prospective, non-randomized multicenter study of
'real-world' outcomes with the WATCHMAN™ Left Atrial Appendage
Closure (LAAC) Device in Europe
will be featured as a late-breaking clinical trial on Tuesday, May 17. The 1,000 patient RESPOND study,
reporting the safety and efficacy of the Lotus™ Transcatheter
Aortic Valve Replacement System used in routine clinical practice
will be presented in a hot line session, also on Tuesday, May 17.
Other presentations and abstracts of interest include data
supporting products in the Boston Scientific interventional
cardiology portfolio. Oral presentations will include the final,
five-year outcomes of the SYNERGY™ Bioabsorbable Polymer
Drug-Eluting Stent System observed in the EVOLVE trial, as well as
two-year clinical outcomes from the EVOLVE II trial, which assesses
the SYNERGY Stent in patients with diabetes. Additionally, there
will be two oral abstracts which will examine the performance of
the Lotus Valve.
"We look forward to facilitating engaging discussions of the
data being presented at this year's EuroPCR congress, including the
late-breaking clinical data relating to the 'real-world'
performance of the WATCHMAN Device, and increasing clinical data
collection for patients treated with the SYNERGY Stent and Lotus
Valve," said Keith Dawkins, M.D.,
global chief medical officer, Boston Scientific. "As reflected by
our robust clinical strategy, we continue to pursue compelling
evidence that supports advancing the standard of care."
SCHEDULE OF PRESENTATIONS OF INTEREST (listed
chronologically)
Tuesday, May 17
- WATCHMAN LAAC Device: EWOLUTION: Three-month outcome of
LAA closure in Europe:
post-procedural drug regimen, impact of center experience and
leakage. Data from the prospective 1,000 patient EWOLUTION
Registry: Dr. M.W. Bergmann, M.D.,
will present on Tuesday, May 17 at
12:08 in the Main Arena.
- The Lotus Valve System: The RESPOND Study: safety and
efficacy of a fully repositionable and retrievable aortic valve
used in routine clinical practice: Professor Volkmar Falk, M.D., will present on Tuesday, May 17 at 16:48 in Room Maillot.
Wednesday, May
18
- WATCHMAN LAAC Device: Short-term (45 days) therapeutic
anticoagulation following LAA closure has no effect on clinical
outcomes: Dr. Maurice Buchbinder,
M.D., will present on Wednesday, May
18 at 9:22 in Room 343.
- The Lotus Valve System: Safety and efficacy of a fully
repositionable and retrievable transcatheter heart valve in
patients with bicuspid aortic valve stenosis: an analysis from the
RESPOND Study: Dr. Dan Blackman,
M.D., will present on Wednesday, May
18 at 11:35 in Room 343.
Thursday, May 19
- SYNERGY Stent: Final five-year clinical outcomes in the
EVOLVE Trial: a randomized evaluation of a novel bioabsorbable
polymer-coated everolimus-eluting stent: Professor Ian Meredith, Ph.D., will present on
Thursday, May 19 at 15:24 in Room
343.
- PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium
Coronary Stent System: PROMUS Element European Post-Approval
(PE PROVE) 4-year outcomes: Four-year results from the multicenter
PE-Prove Registry: outcomes in 1010 unselected patients treated
with a platinum-chromium, everolimus-eluting stent: Dr. Raúl
Moreno, M.D., FESC, will present on Thursday, May 19 at 17:48 in Room 241.
Friday, May 20
- Eluvia™ Drug-Eluting Vascular Stent System: Efficacy of
a novel fluoropolymer-coated paclitaxel-eluting peripheral stent in
a familial hypercholesterolemic swine model of balloon-injured
femoral arteries: Professor T. Thomas
Zeller, M.D., will present on Friday,
May 20, at 10:18 in the Arlequin Room.
- SYNERGY Stent: Two-year clinical outcomes in the EVOLVE
II Trial, Diabetes subset of a bioabsorbable polymer-coated,
everolimus-eluting coronary stent in patients with diabetes:
Professor Ian Meredith, Ph.D., will
present on Friday, May 20 at 11:24 in
Room 252A.
All events are Paris time and
take place at the Palais des Congres. For more information, visit
the Boston Scientific booth located on Level 1, Hall Passy F17.
In the U.S., the Lotus Valve and Eluvia Drug Eluting stent are
investigational devices and are not available for sale.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology
leader for more than 35 years, we advance science for life by
providing a broad range of high performance solutions that address
unmet patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect on Twitter
and Facebook.
CONTACTS:
U.S. Media: Timette Nevala
Boston Scientific Corporation
(763) 494-1284 (office)
Timette.Nevala@bsci.com
European Media: Chiara Ennas
Boston Scientific Corporation
+44 (0) 1442 411618 (office)
Chiara.Ennas@bsci.com
Susie Lisa, CFA
Investor Relations
Boston Scientific Corporation
(508) 683-5565 (office)
investor_relations@bsci.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boston-scientific-announces-schedule-of-presentations-at-europcr-2016-300268212.html
SOURCE Boston Scientific Corporation